Supplements to Improve Memory & Learning

An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous.

A synthetic heptapeptide (an analogue of the ACTH(4-10) fragment) developed in Russia and used there intranasally as a neuroprotective 'nootropic' for ischemic stroke and cognition. Honest appraisal: the mechanistic evidence (BDNF/TrkB induction, monoamine modulation, neuroprotection) is mostly rat and cell studies from a small cluster of Russian labs, and the human data are Russian stroke/cognition trials of variable rigor with very little independent replication. It is NOT a regulated dietary supplement outside Russia — sold 'for research use only', with no Western regulatory approval and unknown long-term safety.

A low-molecular-weight polypeptide complex extracted from cattle/pig brain cortex, registered and very widely prescribed as a neuroprotective 'nootropic' medicine in Russia and CIS countries — so it has real (if mostly Russian-language and methodologically weak) human studies. Cortexin is given by intramuscular injection for stroke, cognitive impairment, epilepsy and pediatric neurology, with claimed neuroprotective and antioxidant effects mediated via glutamatergic/GABAergic activity. Animal work shows it crosses the blood-brain barrier and binds AMPA/kainate/GABA receptors. But the honest picture is sobering: in a rigorous double-blind rodent stroke comparison, cortexin was no better than saline (only cerebrolysin beat placebo), and Russian human trials are typically small, unblinded, single-center, and often show cortexin underperforming comparator drugs. It is NOT FDA-approved or a dietary supplement. Treat the neuroprotection claims as weakly evidenced.

A synthetic angiotensin-IV-derived peptide developed as a procognitive/anti-dementia research compound, promoted online as a potent nootropic. Honest appraisal: all efficacy data are in rodents and cell culture — there are no published human trials. Research-use-only.

A century-old dye and approved drug for methemoglobinemia, used grey-market at low doses as a mitochondrial 'nootropic' and longevity aid. Small human brain-imaging trials suggest low doses can modestly aid memory/oxygen metabolism; longevity/skin evidence is preclinical. Narrow safe-dose window and real interactions (serotonin syndrome). Off-label/research use, not a supplement.

A racetam-class nootropic and high-affinity choline-uptake (HACU) enhancer studied preclinically for memory and briefly in a Phase-2 depression/anxiety program that produced only modest, largely unpublished results. Almost all of the evidence is rodent and in-vitro; there is no peer-reviewed human efficacy data, and it is sold grey-market — not a dietary supplement.

A racetam-class nootropic (NS-105 / NFC-1) whose human evidence is unusually thin. It was originally developed in the 1990s as an oral drug for vascular dementia / cerebrovascular disease — that program was discontinued. It resurfaced for a narrow, mutation-selected indication: one small open-label study (Elia 2018, 30 adolescents) found symptom improvement in teens with ADHD who carry mutations in mGluR-network genes. The mechanism (mGluR modulation, GABA-B receptor upregulation, cholinergic anti-amnesic effects) is grounded in 1990s rat work. It is sold grey-market as a research chemical — not an approved drug, not a dietary supplement, and not a longevity compound.

A grey-market 'research chemical' sold online as a memory-enhancing nootropic — IDRA-21 is a benzothiadiazine AMPAKINE, a positive allosteric modulator of AMPA glutamate receptors that slows their desensitization and so enhances glutamatergic transmission. The CRITICAL fact is the absence of human evidence: there are NO human clinical trials of IDRA-21. Its entire evidence base is rodent and non-human-primate behavioural studies plus in-vitro electrophysiology — work in which it improved learning/memory tasks and was reported several-fold more potent than the prototype ampakine aniracetam. That is genuinely promising preclinical pharmacology, but it has never been tested in people for either benefit or safety, and AMPA potentiation carries a theoretical EXCITOTOXICITY / seizure risk with chronic or high-dose use. Layered on top is grey-market reality: material of unverified identity, purity and dose, taken with no medical supervision. It is NOT an approved medicine, NOT a dietary supplement, and there is no human use this library can recommend. Informational, harm-reduction entry only — the honest takeaway is that IDRA-21 is essentially unstudied in humans.

A grey-market 'research chemical' sold online as a potent nootropic — sunifiram (DM-235) is a piperazine-based experimental cognition enhancer, a structural simplification of the racetam piracetam. The CRITICAL fact is the nature of its evidence: the ENTIRE evidence base is rodent and in-vitro pharmacology, with NO human clinical trials of any kind — no efficacy data, no safety data, and no pharmacovigilance on the material people actually buy. In rodents, sunifiram has anti-amnesic and memory-enhancing effects at very low doses, acting by potentiating AMPA receptors (ampakine-like) and the glycine site of NMDA receptors, enhancing cholinergic signalling, and driving downstream CaMKII / PKCα / BDNF cascades that strengthen hippocampal long-term potentiation. None of that has ever been tested in a person. It is sold as an unregulated 'research chemical' with no approval, no human safety data, unknown long-term effects, and unverified identity, purity and dose, with anecdotal reports of stimulation and overstimulation. The presumed harms are excitatory: anxiety, insomnia, headache, and a theoretical excitotoxicity concern from chronically potentiating AMPA/NMDA signalling — all UNSTUDIED in humans. It is NOT an approved medicine, NOT a dietary supplement, and there is no human use this library can recommend. Informational, harm-reduction entry only — the honest takeaway is that sunifiram's benefit and safety in humans are entirely unstudied.

A grey-market 'research chemical' sold online as a high-potency nootropic — unifiram (DM-232) is an experimental piperazine-class cognition enhancer that came out of academic work (University of Florence, ~2000) simplifying the racetam scaffold, and is the close structural cousin of sunifiram (DM-235). The CRITICAL fact is the depth of the evidence gap: there are NO human clinical trials of unifiram — not one. The ENTIRE evidence base is rodent and in-vitro pharmacology, where DM-232 reversed chemically-induced amnesia in mice at strikingly low doses (active around 0.001 mg/kg) and increased acetylcholine release and AMPA-mediated excitatory transmission in rat brain slices. It is even LESS studied than the already-grey-market sunifiram, with no human efficacy data, no human safety data, and no pharmacovigilance on the powder people actually buy. Its presumed mechanism is excitatory/ampakine-like and cholinergic, so stimulant-type harms — overstimulation, anxiety, insomnia — are plausible but entirely uncharacterised in people. Layer on the grey-market reality (unverified identity, purity and dose, often sold 'not for human consumption'), and the honest takeaway is that unifiram is an essentially unstudied-in-humans laboratory cognition enhancer, NOT an approved medicine, NOT a dietary supplement, and not a use this library can recommend. Informational, harm-reduction entry only.